Abstract
SUMMARY
Pseudophakic
cystoid macular edema is a complication which can precede cataracts surgeries
that performed intensely in ophthalmology practice. In this case report, three
cases that underwent uncomplicated cataract surgery and with symptomatic
psuedophakic cystoid macular edema occurrence were presented and risk factors
and treatment efficiencies were evaluated. Among these three cases, the
cessation of non-steroidal anti-inflammatory drop in the first case, epiretinal
membrane on the macula and prostaglandin analogue use in the second case and
age related macular degeneration in the third case were determined as the risk
factors. Although the central macular thickness exceeded 800 µ in two of the
cases medical treatment was initiated. Cystoid macular edema was resolved with
this treatment and there was no need for invasive treatments. As a
conclusion, we think that topical and oral medical treatment as the first line
therapy for the patients with pseudophakic cystoid macular edema can be
efficient.
References
- 1. Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V. Pseudophakic cystoid macular edema: update 2016. Clinical interventions in aging. 2016; 11:1221-9.
- 2. Guo S, Patel S, Baumrind B, Johnson K, Levinsohn D, Marcus E, et al. Management of pseudophakic cystoid macular edema. Survey of ophthalmology. 2015; 60:123-37.
- 3. Kessel L, Tendal B, Jorgensen KJ, Erngaard D, Flesner P, Andresen JL, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology. 2014; 121:1915-24.
- 4. McCafferty S, Harris A, Kew C, Kassm T, Lane L, Levine J, et al. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC ophthalmology. 2017; 17:16.
- 5. Mitropoulos PG, Chatziralli IP, Peponis VG, Drakos E, Parikakis EA. Intravitreal Ranibizumab for the Treatment of Irvine-Gass Syndrome. Ocular immunology and inflammation. 2015; 23:225-31.
- 6. Garcia JM, Isaac DL, Avila MP. Dexamethasone 0.7 mg implants in the management of pseudophakic cystoid macular edema. Arquivos brasileiros de oftalmologia. 2016; 79:113-5.
- 7. Lin CJ, Tsai YY. Use of Aflibercept for the Management of Refractory Pseudophakic Macular Edema in Irvine-Gass Syndrome and Literature Review. Retinal cases & brief reports. 2016.
Abstract
ÖZET
Psödofakik
kistoid maküla ödemi göz hastalıkları pratiğinde yoğun uygulanan katarakt
cerrahisinin karşılaşılabilen bir komplikasyonudur. Bu çalışmada, kliniğimizde
komplikasyonsuz katarakt cerrahisi geçiren ve sonrasında semptomatik psödofakik
kistoid maküla ödemi gelişen üç olgu sunulmuş ve risk faktörleri ve tedavi
etkinliği değerlendirilmiştir. Üç vakadan ilk olgu non-steroid antiinflamatuar
ilacını kontrolsüz olarak kesmiş olması, ikinci olguda makülada epiretinal
membran ve prostoglandin analoğu kullanımı olması, üçüncü olguda ise yaşa bağlı
maküla dejenerasyonu bulgularının olması risk faktörleri olarak
saptanmıştır. Santral maküla kalınlığının iki vakada 800 µ aşmasına
rağmen medikal tedavi başlanılmış ve bu tedavi ile kistoid maküla ödeminin
gerilemiş ve invazif tedavilere gerek kalmamıştır. Sonuç olarak psödofakik
kistoid maküla ödemi gelişen hastalarda da öncelikle topikal ve oral olarak
başlanan medikal tedavinin etkili olabileceği düşünmekteyiz.
References
- 1. Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V. Pseudophakic cystoid macular edema: update 2016. Clinical interventions in aging. 2016; 11:1221-9.
- 2. Guo S, Patel S, Baumrind B, Johnson K, Levinsohn D, Marcus E, et al. Management of pseudophakic cystoid macular edema. Survey of ophthalmology. 2015; 60:123-37.
- 3. Kessel L, Tendal B, Jorgensen KJ, Erngaard D, Flesner P, Andresen JL, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology. 2014; 121:1915-24.
- 4. McCafferty S, Harris A, Kew C, Kassm T, Lane L, Levine J, et al. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC ophthalmology. 2017; 17:16.
- 5. Mitropoulos PG, Chatziralli IP, Peponis VG, Drakos E, Parikakis EA. Intravitreal Ranibizumab for the Treatment of Irvine-Gass Syndrome. Ocular immunology and inflammation. 2015; 23:225-31.
- 6. Garcia JM, Isaac DL, Avila MP. Dexamethasone 0.7 mg implants in the management of pseudophakic cystoid macular edema. Arquivos brasileiros de oftalmologia. 2016; 79:113-5.
- 7. Lin CJ, Tsai YY. Use of Aflibercept for the Management of Refractory Pseudophakic Macular Edema in Irvine-Gass Syndrome and Literature Review. Retinal cases & brief reports. 2016.
Details
| Subjects | Clinical Sciences |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | August 2, 2017 |
| Published in Issue | Year 2017 Volume: 1 Issue: 1 |
Cite
Ahi Evran Medical Journal is indexed in ULAKBIM TR Index, Turkish Medline, DOAJ, Index Copernicus, EBSCO and Turkey Citation Index. Ahi Evran Medical Journal is periodical scientific publication. Can not be cited without reference. Responsibility of the articles belong to the authors.
